Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Becton Dickinson; Genome ID Group; ResearchDx; ACMG, 5AM Solutions

NEW YORK (GenomeWeb News) – Becton Dickinson this week said its board has declared a quarterly dividend of $.545 per share payable on Dec. 31 to shareholders of record on Dec. 10. At the current rate, the annual dividend for Fiscal Year 2014 would be $2.18 per share, the company said.

The Genome ID Group has established The Center for Advanced Forensic DNA Analysis in Greenville, N.C. The center is a joint effort of Pitt County, Greenville, and the NC Biotech Center and currently has 10 employees with plans to increase that number to 130 and expand within its 11,000 square feet building "in line with business growth," it said. The new center is a full service forensic genomics lab, and offers forensic analysis of biological evidence from crime scenes.

Contract diagnostics organization ResearchDx has expanded into India, where it will partner with Indian firms developing companion diagnostics and in vitro diagnostic products. It also will help companies seeking CLIA accreditation, and ISO and CAP certification.

The American College of Medical Genetics and Genomics has extended its contract with 5AM Solutions as part of ACMG's recent five-year contract extension with the Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Newborn Screening Translational Research Network Coordination Center. 5AM Solutions, an informatics and software solutions firm, will continue to "enhance the existing web-based Virtual Repository for Dried Blood Spots and the NBSTRN website," as part of the contract extension with ACMG, it said.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.